BIOQ Share Price Performance
US$43.19
-26.81 (-38.30%)
Price US$43.19
Share PriceUS$43.19
BIOQ Community Narratives
There are no narratives available yet.
Recent BIOQ News & Updates
No updates
Bioqual, Inc. Key Details
Last Reported Earnings
Feb 28, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -2.38
- Gross Margin
- -8.93%
- Net Profit Margin
- -4.34%
- Debt/Equity Ratio
- 0%
Bioqual, Inc. Competitors
About BIOQ
- Founded
- 1981
- Employees
- n/a
- CEO
- WebsiteView website
Bioqual, Inc. provides in-vivo and in-vitro pre-clinical research services to commercial and government clients in the United States. The company provides research services in the areas of COVID-19, AIDS, influenza, RSV infection, and flavivirus infections, including zika, dengue, malaria, hepatitis, and cancer. Its services also include sample processing, virus stock generation, quantitation of infectious virus, virus neutralization assays, hemagglutination inhibition assay, quantitative PCR, antigen and antibody ELISA detection assays, flow cytometry, lymphocyte proliferation, and other cell-based assays. In addition, the company provides animal research model related services. Bioqual, Inc. was founded in 1981 and is based in Rockville, Maryland.
U.S. Market Performance
- 7 Days: -1.2%
- 3 Months: 13.1%
- 1 Year: 22.8%
- Year to Date: 7.3%
Over the last 7 days, the market has dropped 1.2%, driven by a loss of 4.7% in the Consumer Discretionary sector. In contrast to the last week, the market is actually up 23% over the past year. Earnings are forecast to grow by 15% annually. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading